# NUZ-001

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/nuz-001
Canonical HTML page: https://getbiobrief.com/entity/nuz-001

## Timeline

- **2026-Q4**: Interim Analysis — Expected window for preliminary safety and biomarker data review by the trial committee.
- **2026-02-26**: Dosing Initiation — First patient dosed with NUZ-001 in the multi-center Phase 2/3 study.
- **2024-12**: Trial Selection — NUZ-001 selected as a new regimen for the HEALEY ALS Platform Trial.

## Recent coverage (1 stories)

### Neurizon Begins Dosing NUZ-001 in Landmark HEALEY ALS Platform Trial
2026-02-26 22:41:08 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.
Full story: https://getbiobrief.com/story/neurizon-nuz-001-healey-als-trial-dosing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.